Sunshine Biopharma Inc

Sunshine Biopharma Inc(SBFM)の株式分析

$2.705

-0.083 (-3.05%)終値時点

Loading chart…
高値
2.850
始値
2.730
出来高加重平均価格
2.74
出来高
36.20K
時価総額
8.33M
安値
2.680
売買代金
99.37K
EV/EBITDA(TTM)
1.46

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

AI分析 of Sunshine Biopharma Inc (SBFM)

売り

Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.

バリュエーション指標

Sunshine Biopharma Inc(SBFM)の現在の予想PERは0.00で、5年平均は-1.93です。

予想PER

適正
5年平均 P/E
-1.93
現在のP/E
0.00
割高
0.49
割安
-4.34

予想EV/EBITDA

大幅な割高
5年平均 EV/EBITDA
0.10
現在のEV/EBITDA
1.46
割高
0.45
割安
-0.25

予想PSR

適正
5年平均 P/S
0.16
現在のP/S
0.05
割高
0.39
割安
-0.07

Alphio AI による SBFM の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%SBFM

$1.99

シナリオ価格

基

基本

基本 · 50%SBFM

$1.88

シナリオ価格

弱

弱気

弱気 · 25%SBFM

$1.86

シナリオ価格

SBFM を保有するクジラ

L

L1 Capital Pty. Limited

+ を保有SBFM

+9.12%

3か月リターン

イベントタイムライン

2026-10-08 (ET)

09:00:00

Sunshine Biopharma Prices Public Offering at $6 Million

2026-09-24 (ET)

09:30:00

Sunshine Biopharma Launches 4mg and 8mg Ondansetron Generics in Canada

2026-09-16 (ET)

09:30:00

Sunshine Biopharma Advances Coronavirus Drug Candidate into IND Studies

2026-08-31 (ET)

09:30:00

Sunshine Biopharma Receives Approval for Atenolol Tablets

2026-08-28 (ET)

16:30:00

Sunshine Biopharma Files to Sell 24.48M Shares of Common Stock

ニュース

SBFM のよくある質問 — Alphio AI が回答

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める